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Background: Resveratrol (3,5,4’ - trihydroxy-trans-stilbene), a widely distributed natural stilbenoid, was proposed to
account for the unique effects of red wine on life span and health. It has been reported to possess various
biological and pharmacological activities, such as anti-oxidant, anti-inflammatory, and anti-carcinogenic effects.
Here, using whole-cell patch-clamp techniques and behavioral analyses, we investigated whether resveratrol and
other stilbenoids can modulate TRP channels in sensory neurons in vitro, and have analgesic effects in vivo.
Results: We found that resveratrol dose-dependently suppressed the allyl isothiocyanate (AITC)-induced currents
(IAITC) in HEK293 cells that express TRPA1, as well as in rat dorsal root ganglion (DRG) neurons. Instead, pinosylvin
methyl ether (PME), another derivate of stilbene which has a similar structure to resveratrol, dose-dependently
blocked the capsaicin-induced currents (ICAP) in HEK293 cells that express TRPV1 as well as in DRG neurons.
Interestingly, resveratrol had no inhibitory effect on the ICAP, and PME had no effect on the IAITC. Otherwise, trans-
stilbene showed no any effect on IAITC or ICAP. The concentration response curve of AITC showed that resveratrol
inhibited the action of TRPA1 not by changing the EC50, but by suppressing the AITC-induced maximum response.
By contrast, the inhibition of TRPV1 by PME did not change the capsaicin-induced maximum response but did
cause a right shift of the EC50. Moreover, pre-administration of resveratrol suppressed intraplantar injections of AITC-
evoked nocifensive behaviors, as well as that PME suppressed capsaicin-evoked one.
Conclusions: These data suggest that resveratrol and other stilbenoids may have an inhibitory effect on TRP
channels. In addition, these stilbenoids modulate TRP channel activity in different ways.Background
Stilbenoids are bioactive compounds that show beneficial
effects on human health, such as anti-tumor activity and
increased rate of survival. Resveratrol (3,5,4’ - trihydroxy-
trans-stilbene) is a representative stilbenoid which consists
of two aromatic rings that are attached by a methylene
bridge (Figure 1). It is a natural phenol and phytoalexin,
produced biologically by 72 different plant species, espe-
cially grapevines, pine trees, and legumes [1]. Resveratrol
was first isolated from the roots of white hellebore
(Veratrum grandiflorum O. Loes), and from the roots
of Polygonum cuspidatum, a plant used in traditional
Chinese and Japanese medicine [2,3]. The concentration of
resveratrol in grapes skin is about 0.1 mg/100 g of fresh* Correspondence: ydai@huhs.ac.jp
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reproduction in any medium, provided the orweight [4]. Resveratrol has been reported to have potent
anti-aging, anti-inflammatory, anti-cancer anti-oxidative,
and chemo-protective characteristics [5-11]. Recently, some
studies have indicated that resveratrol has analgesic proper-
ties against both acute and chronic pain that is triggered by
nocifensive stimuli, inflammation, or nerve-injury [9-14].
Mechanisms of this analgesic action have been suggested to
be alterations of the expression of serum tumor necrosis
factor-alpha, whole brain nitric oxide in the diabetic rat
model [14], reduction of expression of cyclooxygenase-2 in
the inflammatory pain model [10], or inhibition of cyclin-
dependent kinase 5 activity in primary afferent neurons
[15]. However, the direct molecular target of resveratrol has
been elusive.
Since the discovery of the Drosophila melanogaster
transient receptor potential (trp) gene, it has become
known that mammalian genomes contain 28 homolo-
gous genes encoding proteins that are capable of
forming a large variety of cationic channels, usually withThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 Chemical structures of trans-stilbene, resveratrol and pinosylvin methyl ether.
Yu et al. Molecular Pain 2013, 9:3 Page 2 of 11
http://www.molecularpain.com/content/9/1/3permeability to sodium and calcium [16]. TRPV1 and
TRPA1 are members of branch V and A of the TRP fam-
ily of cation channels respectively, and are expressed by
a subset of small-sized DRG or trigeminal ganglia
neurons in neonatal rats, adult rats and mice [17,18]. It
is well known that TRPV1 is activated by capsaicin,
protons, or heat (with a thermal threshold > 43C), which
cause pain in vivo [17,19]. Analyses of mice lacking
TRPV1 have shown that it is essential for selective moda-
lities of pain sensation, as well as for tissue injury-induced
thermal hyperalgesia [20]. Like TRPV1, TRPA1 is activated
by various kinds of noxious compounds (such as allyl
isothiocyanate (AITC), cinnamaldehyde, cannabinoids,
and allicin) through their ability to covalently modify
cysteine residues in the channel proteins [21-26]. TRPA1
has also been reported to be activated by bradykinin,
intracellular alkalization, and the endogenous aldehyde,
4-hydroxynonenal [21,27,28]. Studies using knockout mice
demonstrated that TRPA1 is an important component of
the transduction machinery through which environmental
irritants and endogenous proalgesic agents depolarize
nociceptors to elicit inflammatory pain [29]. There is no
doubt that TRPV1 and TRPA1 are critical molecules for
the detection and modulation of pain sensations.
Using patch-clamp and behavior analyses, we investigated
the pharmacological effects of resveratrol and related
stilbenoids on these two pain-related TRP channels, TRPV1
and TRPA1. We observed that resveratrol significantly
inhibited IAITC, but not ICAP, both in heterologous HEK293
cells and DRG neurons. Resveratrol also inhibited AITC-
induced nocifensive behavior in adult rats. By contrast,
pinosylvin methyl ether (PME), an analog of resveratrol,
inhibited ICAP and nocifensive behavior. The pathway
targeted by resveratrol and other related stilbenoids may
become useful for developing treatments for many painful
diseases in the future.
Results
Resveratrol suppresses IAITC but not ICAP in heterologous
HEK293 cells
We examined the effects of resveratrol on the IAITC in
HEK293 cells expressing mTRPA1. The AITC (100 μM)
did not induce any significant current in untransfected
HEK293 cells. In mTRPA1 expressing HEK293 cells, theIAITC (AITC, 100 μM) underwent a fast activation com-
ponent and then by rapid inactivation (desensitization).
After 3 min pretreatment of resveratrol (30 μM), not only
was the time of the activation component clearly extended,
but the magnitude of IAITC was significantly suppressed
(Figure 2A). The inhibition of IAITC by resveratrol
appeared from a low concentration (0.3 μM) with an IC50
value of approximately 0.75 μM (Figure 2B).
To examine how resveratrol changes TRPA1 responsive-
ness, we measured IAITC density by applying a range of
concentrations of AITC in the absence or presence
resveratrol. We found that treatment with resveratrol
(30 μM, 3 min) strongly suppressed IAITC at the maximum
response (−115.2 ± 5.9 pA/pF for AITC vs −15.1 ± 1.8 pA/
pF for AITC with resveratrol) without affecting EC50
(61.2 μM for AITC vs 61.7 μM for AITC with resveratrol)
(Figure 2C). 2-aminoethoxy diphenyl borate (2APB), as a
non-electrophilic agonist, is known to activate TRPA1 with-
out covalent modification of the cysteine residues. To fur-
ther investigate the inhibition mechanism, the effect of
resveratrol on 2APB-induced currents in mTRPA1-
transfected HEK293 cells was tested. We found that
resveratrol also significantly reduced 2APB-induced current
in HEK293 cells expressing mTRPA1 (−42.1 ± 14.0 pA/pF
for 2APB without resveratrol, n=11; -6.4 ± 2.4 pA/pF for
2APB with resveratrol, n=6, p < 0.05) (Figure 2D, E). We
confirmed that application of resveratrol alone at less than
30 μM causes no change of membrane currents in HEK293
cells expressing mTRPA1. These data clearly indicate a
suppressive effect of resveratrol on TRPA1 channel acti-
vity, and this effect was not dependent on agonist’s
electrophilicity. We also tested if resveratrol had any
pharmacological actions on another pain-related TRP
channel, TRPV1. In contrast to TRPA1, resveratrol at
30 μM did not significantly inhibit ICAP (capsaicin, 20 nM)
in HEK293 cells expressing rTRPV1 (Figure 2F, G) (−27.3 ±
7.3 pA/pF for capsaicin without resveratrol, n=6; -27.7 ±
5.4 pA/pF for capsaicin with resveratrol, n=5, p > 0.05).
Resveratrol suppresses IAITC in DRG neurons
Because cell types differ in their membrane composition,
we asked whether resveratrol would also suppress
TRPA1 channels in sensory neurons. We then tested the






























































































Figure 2 Resveratrol suppresses TRPA1 currents, but not TRPV1 currents in a concentration dependent manner in transfected HEK293
cells. A: Representative traces from whole-cell patch-clamp experiments show the IAITC (AITC, 100 μM) in the absence (left) or presence (right) of
resveratrol (RES, 30 μM). B: Dose–response curve showing inhibition of IAITC by RES. Each point represents relative IAITC with different concentration of
RES treatment normalized to the IAITC without RES treatment (mean ± SEM, n = 6–11). IC50 = 0.75 μM. C: Concentration curves of IAITC in the absence
(open circles) and presence (filled circles) of RES. Note the maximum response was inhibited without changing the EC50 (61.2 μM for AITC, 61.7 μM for
RES + AITC). D: Representative traces show the I2APB (2APB, 400 μM) in the absence (left) or presence (right) of resveratrol (RES, 30 μM). E: The bars
graph shows RES significantly inhibits I2APB density (pA/pF). * p < 0.05, unpaired t – test. F: Representative traces show the ICAP (capsaicin, 20 nM) in the
absence (left) or presence (right) of RES. G: Bars graph shows no effect of RES on ICAP. Numbers in parenthesis indicate cells tested. AITC or capsaicin
was perfused until current reaching the peak. Holding potential (Vh) = −60 mV in all experiments.
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clamp experiments to detect the TRPA1 current. A pre-
vious study indicated that while there are AITC-sensitive
cells in TRPA1 knockout mice, these are not where the








Figure 3 Resveratrol suppresses IAITC in DRG neurons. A, B: Representa
(RES, 30 μM). C: Resveratrol significantly inhibits IAITC (pA). Numbers in pare
perfused until current reaching the peak. Holding potential (Vh) = −60 mVa TRPA1-mediated event, capsaicin at 1 μM was applied
at the end of recording using the patch-clamp prepa-
ration (see Methods section). We observed that AITC at
300 μM induced a large inward current in DRG neurons
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in all experiments.
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(−1228.8 ± 270.9 pA, n=5 for AITC without resveratrol
treatment, vs -127.7 ± 20.8 pA, n = 5 for AITC with
resveratrol treatment, p < 0.05). We confirmed that ap-
plication of resveratrol alone at 30 μM caused no change
of membrane currents in DRG neurons. Together, these
data indicate that resveratrol suppress IAITC both in a
heterologous expression system and in sensory neurons.
PME suppresses ICAP but not IAITC in heterologous HEK293
cells and DRG neurons
We also tested if another derivate of stilbenoid, PME,
which shares a structure similar to resveratrol (Figure 1)
could modulate TRP channels. In contrast to resveratrol,
PME showed significant suppression on TRPV1 activity.
In voltage-clamp experiments, low doses of capsaicin (20
nM) evoked small inward currents in the HEK293 cells.
In the absence of extracellular calcium, no change was
observed in the magnitude of the responses that were
evoked by repetitive capsaicin applications (Figure 4A).
After 2 min pretreatment with 30 μM PME, the same
doses of capsaicin produced much smaller current





































Figure 4 PME suppresses ICAP in transfected HEK293 cells. A, B: Repres
presence (B) of PME (30 μM). Cells were perfused for 2 min with solution c
inhibit ICAP dose dependently. Numbers in parentheses indicate cells tested
PLSD. D: ICAP concentration-response curves for TRPV1 activation in the abs
were normalized to the currents maximally activated by 1 μM capsaicin (CA
the Hill equation. EC50 = 42.6 nM and EC50 = 148.2 nM in the absence or p
used to prevent TRPV1 desensitization in all experiments. Cells were perfusfor control without PME. p < 0.01) (Figures 4B and C).
The suppression of ICAP by PME was dose-dependent
(Figure 4C). We confirmed that application of PME alone
at 30 μM caused no change of membrane currents in
HEK293 cells expressing rTRPV1. To examine how PME
changes TRPV1 responsiveness, we measured ICAP in sin-
gle cells by serially applying a range of concentrations of
capsaicin in the absence or presence of PME (30 μM). The
currents were normalized to the maximal current
(induced by capsaicin, 1 μM) without PME to each cell.
Maximal currents in the presence of PME were almost the
same as those obtained in the absence of PME. The result-
ant dose–response curves clearly demonstrate that PME
suppresses TRPV1 responsiveness by increasing EC50
values without altering maximal responses (EC50 from
42.6 nM to 148.2 nM) (Figure 4D).
We also recorded ICAP on rat DRG neurons. Repeated
treatment with capsaicin (30 nM) induced inward
currents in small-sized cells with inconspicuous tachy-
phylaxis in the calcium-free extracellular solution
(Figure 5A). We confirmed that application of PME
alone at 30 μM caused no change of membrane currents
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entative trace shows ICAP (capsaicin, 20 nM) in the absence (A) or
ontaining PME before reapplication of the capsaicin (CAP). C: PME
. ** p < 0.01 versus 0 μM PME, one-way ANOVA followed by Fisher’s
ence (open circles) or presence (filled circles) of PME (30 μM). Currents
P) in the absence of PME. The figure shows averaged data fitted to
resence of PME, respectively. Calcium-free extracellular solutions were

































































Figure 5 PME inhibits ICAP but not IAITC in a concentration-dependent manner in DRG neurons. A, B: Representative trace shows ICAP in
the absence (A) or presence (B) of PME (30 μM). C: PME inhibited ICAP in a dose-dependent manner. ** p < 0.01 versus control, one-way ANOVA
followed by Fisher’s PLSD. Cells were perfused with capsaicin (30 nM) until the current reaching peak in A-C. D: PME showed no inhibitory effect
on IAITC (AITC, 100 μM). Numbers in parenthesis indicate cells tested. Calcium-free extracellular solutions were used to prevent TRPV1
desensitization in A-C.
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pre-treatment of PME (30 μM, 2 min) significantly
inhibited ICAP (Figure 5B). The suppression of the
TRPV1 responsiveness by PME was dose-dependent (1.0
± 0.1 fold, n=6 for control; 0.5 ± 0.1 fold, n=5 for PME
at 10μM; 0.2 ± 0.1 fold, n=6 for PME 30 μM; 0.1 ± 0.01
fold, n=4 for PME 100μM; p < 0.01 vs. control for all
concentrations) (Figure 5C). In contrast to resveratrol,
PME (30 μM) did not show any effect on IAITC in DRG
neurons (0.9 ± 0.1 fold, n=9 for control, 1.0 ± 0.2, n=5
for PME, p > 0.05) (Figure 5D).
Trans-stilbene showed no modulatory effect on either
TRPA1 or TRPV1 channels
Both resveratrol and PME are structural derivatives from
stilbene (Figure 1). Resveratrol differs from trans-
stilbene by having three hydroxyls attached to its phenyl
groups, while PME differs from trans-stilbene by having
a hydroxyl and a methoxyl attached to its phenyl groups.
Both of the derivatives show inhibitory modulation on
TRP channels. We then tested the effect of trans-
stilbene with the basal stilbene structure on the TRPchannels. Trans-stilbene was used at 30 μM, the same
concentration as resveratrol and PME. In electrophysio-
logical experiments, we found that trans-stilbene has no
significant effect on either TRPA1 or TRPV1 in heterol-
ogous HEK293 cells. Pre-treatment with trans-stilbene
for 3 min did not suppress either the IAITC (AITC
30 μM) or ICAP (capsaicin 20 nM) (IAITC = −33.4 ± 13.3
pA/pF, n=7 for control; -35.3 ± 10.1 pA/pF, n=5 for trans-
stilbene, p > 0.05) (ICAP = −38.2 ± 12.5 pA/pF, n=7 for con-
trol; -40.4 ± 7.0 pA/pF, n=5 for trans-stilbene, p > 0.05)
(Figure 6).
Resveratrol/PME reduce the AITC-/capsaicin- induced
nocifensive behaviors
TRPA1 and TRPV1 are known to be expressed on sen-
sory neurons and act as an important component of
pain. If resveratrol/PME can suppress the TRPA1/
TRPV1 activation, pain sensation that is caused through
the TRPA1/TRPV1 channels may also be suppressed by
resveratrol/PME treatment. To this end, we performed
intraplantar injections with AITC or capsaicin to the rat
hind paw, and recorded the AITC- or capsaicin-induced
Figure 6 Trans-stilbene shows no effect on either IAITC or ICAP in transfected HEK293 cells. A: Bar graph shows the effect of trans-stilbene
(30 μM, 3 min) on IAITC (AITC, 30 μM). (B) Bar graph shows the effect of trans-stilbene (30 μM, 3 min) on ICAP (capsaicin, 20 nM). Cells were
perfused with either AITC or capsaicin until the currents reached their peak. Numbers in parentheses indicate cells tested.
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previous studies, both AITC and capsaicin injections
induced a significant flinch behavior of the injected hind
paw during the 30 min post-injection period, whereas
such behaviors were not observed in vehicle-injected
rats (liquid paraffin or saline injection).
Then we tested the effects of pretreatment resveratrol
or PME on AITC- or capsaicin-induced behaviors. We
found these two derivatives of stilbene did not cause any
inflammatory reactions (e.g. redness, swelling) or acute
nocifensive behavior (e.g. paw lifting, flinching or
licking). After pre-treatment with resveratrol (300 μM)
or PME (300 μM), AITC or capsaicin was injected into
the same area of the hind paw, as previously described
[30,31]. Pre-treatment with resveratrol significantly
decreased the number of paw flinches induced by AITC
(but not capsaicin) from 15 min post-injection period in
a continuously gradual manner (Figure 7A, B). Pre-
treatment with PME also significantly decreased the
number of paw flinches induced by capsaicin (but not
AITC) injection (Figure 8A, B). However, the AITC- or
capsaicin-induced paw licks were not significantly
changed by pretreatment of either resveratrol or PME,
respectively (Figure 7C, D and Figure 8C, D).
Discussion
Resveratrol has been shown to have chemo-preventive,
cardio-protective, anti-aging, anti-oxidative and anti-
nociceptive properties [32]. For the first time, we areable to report that resveratrol is a potent inhibitor of
TRPA1 in vitro and in vivo. Given that TRPA1 plays
important roles in pain transduction and oxidative
stress response [28,33,34], our observations imply that the
reported anti-nociceptive and anti-oxidative properties of
resveratrol are possibly the results of the TRPA1 activity
inhibition.
In this study, we found that resveratrol could inhibit
the IAITC in both heterologous HEK293 cells and DRG
neurons in a dose-dependent manner. Two potential
mechanisms are suggested to be involved in this inhibi-
tory regulation. One would be that resveratrol inhibits
the single channel conductance or open probability. The
other would be that resveratrol decreases the channel
density of TRPA1 on cell membranes. In the present
study, the concentration-response curves of AITC
resulting from the effect of resveratrol (Figure 2C)
revealed that resveratrol suppressed the maximal re-
sponse of AITC without conspicuously altering EC50, in-
dicating that resveratrol inhibits TRPA1 activity through
a non-competitive (to AITC) mechanism. Resveratrol
might inhibit TRPA1 intracellularly by affecting the co-
valent modification of cysteine residues by AITC in the
channel protein and subsequently inhibiting the channel
conductance or open probability. However, the lack of
effect of resveratrol on the EC50 for AITC-induced
currents (Figure 2C), in addition to that resveratrol also
suppressed the 2APB-induced currents (Figure 2D, E),
indicated that the covalent modification of cysteine
A B
DC
Figure 7 Resveratrol but not PME inhibits AITC-induced pain behavior. Resveratrol (RES, 300 μM, 50 μl) or PME (300 μM, 50 μl) was pre-
treated subcutaneously 5 min before AITC (3% in 50 μl liquid paraffin) or vehicle (VEH) injection. A, C: Time course of the number of paw flinches
(A) or duration of paw licks (C) induced by AITC or VEH after resveratrol or PME pretreatment, respectively. The number of flinches and duration
of licks were counted per 5 min interval in the initial 30 min period after AITC injection. * p < 0.05, ** p < 0.01, versus VEH + AITC (one-way
ANOVA followed by Fisher’s PLSD); # p < 0.05, versus VEH + AITC group (two-way repeated ANOVA followed by Fisher’s PLSD). B, D: Cumulative
number of paw flinches (B) or duration of paw licks (D) in the initial 30 min period after AITC - or VEH - injection. $ p < 0.05, versus VEH + AITC,
(one way ANOVA followed by Fisher’s PLSD). Numbers in parentheses indicate number of rats used in each group.
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hibition of TRPA1. Otherwise, resveratrol may decrease
the channel density on cell membranes through promot-
ing receptor internalization or by inhibiting membrane
insertion of TRPA1 channels. TRPA1 may cycle between
the plasma membrane and intracellular compartments,
and the balance between membrane insertion and re-
trieval determines its surface abundance and activity
[35]. A recent report indicated that TRPA1 channel
desensitization in sensory neurons was regulated by intern-
alization of itself [36]. On the other hand, PME inhibited
ICAP. The concentration-response curves of capsaicin
resulting from the effect of PME (Figure 4D) revealed that
PME increased the EC50 of capsaicin without conspicuously
altering maximal response, indicating that the PME inhib-
ition of TRPV1 through a competitive (to capsaicin) mech-
anism, which differs from the resveratrol inhibition TRPA1.
PME may supress the TRPV1 binding affinity for capsaicin,
or modify the channel’s responsiveness to its own ligand.Anyway, the detailed mechanisms of resveratrol/PME regu-
lation on TRPA1/TRPV1 requires further study.
In the present study, consistent with the patch-clamp
data, topical treatment of resveratrol or PME produced a
significantly persistent suppression of the number of paw
flinches induced by intraplantar injection of AITC or cap-
saicin, respectively (Figure 7, 8), indicating resveratrol (or
PME) can suppress the TRPA1 (or TRPV1) activity not
only in vitro but also in vivo. Resveratrol has been reported
to have analgesic properties against acute and chronic pain
that is triggered either by nocifensive stimuli, inflammation
or nerve injury [9-14]. As TRPA1 and TRPV1 in DRG
neurons plays important roles in pain transmission and
neurogenic inflammation, our results indicate that inhib-
ition of IAITC by resveratrol, as well as inhibition of ICAP by
PME, may at least partly account for its analgesic effects
observed in these in vivo studies. These stilbenoids then































minutes after capsaicin or vehicle injection


















































































































Figure 8 PME but not resveratrol inhibits CAP-induced pain behavior. PME (300 μM, 50 μl) or resveratrol (RES, 300 μM, 50 μl) was pre-
treated subcutaneously 5 min before capsaicin (CAP, 0.05% in 50 μl saline with 0.5% tween20) or VEH injection. A, C: Time course of the number
of paw flinches (A) or duration of paw licks (C) induced by capsaicin or VEH after PME or resveratrol pretreatment, respectively. The number of
flinches and duration of licks were counted per 5 min interval in the initial 30 min period after capsaicin or VEH injection. * p < 0.05, ** p < 0.01,
versus VEH + CAP (one-way ANOVA followed by Fisher’s PLSD); ## p < 0.01, versus VEH + CAP group (two-way repeated ANOVA followed by
Fisher’s PLSD). B, D: Cumulative number of paw flinches (B) or duration of paw licks (D) in the initial 30 min period after capsaicin-injection.
$$ p < 0.01, versus VEH + CAP (one way ANOVA followed by Fisher’s PLSD). Numbers in parentheses indicate number of rats used in each group.
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anti-inflammatory, anti-proliferative, anti-angiogenic, and
chemo-protective effects, with those on oxidative stress
being the most important to human health, and possibly
the foundation for some of the other beneficial effects.
However, many signaling pathways are among the mo-
lecular targets of resveratrol, and thus we cannot be cer-
tain exactly what these pathways are at the present time.
In concert, these effects may be beneficial in many
disorders, particularly in diseases where oxidative stress
plays an important role [37]. Oxidative stress results from
metabolic activity or environmental stimuli, and produces
highly reactive chemicals (e.g., H2O2) and oxidizing lipid
products (e.g., 4-hydroxynonenal), which are known to ac-
tivate TRPA1 and subsequently impacts human health
[28,33,38]. Therefore, our finding that resveratrol inhibits
TRPA1 activity may also provide a potential mechanism
for the well-known anti-oxidative properties of resveratrol.
Resveratrol, as well as PME, was initially characterized as
a phytoalexin, which is an anti-microbial substancesynthesized by plants in response to infection [39]. Both of
these derivatives of stilbene can inhibit TRP channels. It
would be interesting to determine if the basal stilbene
structure itself can modulate TRP activity. In the present
study, trans-stilbene did not significantly inhibit either
TRPA1 or TRPV1 (Figure 6), indicating that the modula-
tion mechanism of these stilbenoids may not result from
the direct binding of the basal structure of stilbene with the
TRP domain. An indirect mechanism (for example, via the
intracellular signals downstream stilbenoids) to explain the
modulation of TRP channels by stilbenoids is suggested
and needs to be further investigated.
Conclusion
TRPA1 and TRPV1 are widely expressed channel present
in many organs and tissues, including the respiratory sys-
tem, cardiovascular system, gastrointestinal tract, inner ear,
skin, skeletal muscle, dental pulp, pancreas, as well as the
peripheral and central nervous system. These channels play
important roles in inflammation, oxidative stress, and pain
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the first time that resveratrol and PME can significantly in-
hibit the TRPA1 and TRPV1 activity in vitro and in vivo, re-
spectively. Therefore, the reported anti-nociceptive
activities of resveratrol and PME may be considered to ori-
ginate from TRP channel inhibition.Methods
Animals and agents
All animal experimental procedures were approved by
the Hyogo University of Health Sciences Committee on
Animal Research (#2010-22) and were performed in ac-
cordance with the National Institutes of Health
guidelines on animal care. Adult male Sprague–Dawley
(SD) rats (100–250 g; Japan SLC, Inc, Shizuoka, Japan)
were used for DRG culture and behavioral studies.
Resveratrol (Sigma-Aldrich, St Louis, MO, USA), trans-
stilbene (Sigma-Aldrich) and PME (Oy Arbonova Ab,
Turku, Finland) were prepared from methanol based
stock solutions that had been kept for not longer than 1 -
month at 4C. Otherwise, capsaicin was prepared from
ethanol based stock solution that was kept at −20C. All
compounds were added from these stock solutions to
the recording solution. The final ethanol or methanol
concentration in recording solutions was less than 0.1%.
AITC was from Nacalai tesque (Kyoto, Japan). 2APB
was from Sigma. Glutamax, fetal bovine serum (FBS),
Penicillin–Streptomycin, Earle’s balanced salt solution
(EBSS, Sigma), DMEM, vitamin solution and OPTI-
MEM were from Invitrogen (Carlsbad, CA, USA).Mammalian cell culture
Human embryonic kidney-derived (HEK293) cells were
maintained in DMEM (supplemented with 10% FBS,
2 mM glutamax, Penicillin and Streptomycin) and
transfected with 1 μg of a mouse TRPA1 or a rat TRPV1
(mTRPA1 and rTRPV1 respectively) cDNA by using
Lipofectamine LTX (Invitrogen). The cDNAs were gen-
erous gifts from Dr. Makoto Tominaga. To identify
transfected cells, an enhanced green fluorescence protein
reporter plasmid (BD Bioscience Clontech, CA) was also
transfected at 0.1 μg. For primary culture of DRG
neurons, whole DRGs were collected from the adult SD
rats (100–150 g) using sterile techniques, and placed in
ice-cold EBSS. Adhering fat and connective tissues were
removed in order to isolate the DRGs. Each DRG
neuron was then immediately placed in a medium
consisting of 2ml of EBSS and 1.25 mg/ml of collagenase
P (Sigma), and kept at 37C for 60 min with occasional
agitation. After dissociation of the DRG cells, this cell
suspension was centrifuged for 5 min at 1000 rpm and
the cell pellet was re-suspended in EBSS supplemented
with 10% FBS, 2mM Glutamax, Penicillin, Streptomycinand vitamin solution. Recombinant rat nerve growth fac-
tor (100 ng/ml, Sigma) was added to the medium.
Electrophysiology
Whole-cell patch-clamp recordings were performed 2 -
days after transfection of mTRPA1 cDNA, or 1 day after
transfection of rTRPV1 cDNA to HEK293 cells, or 1 day
after dissociation of the DRG neurons. Voltage-clamp
experiments were performed at -60mV holding poten-
tial, and recordings were sampled at 5 kHz and filtered
at 2 kHz. Current densities (pA/pF) and normalized
currents were measured. The current magnitude was
quantified by peak current amplitude in all experiments.
A normalized current was obtained from dividing the
third application-induced current to the second one, and
adopted just in case the magnitude of the second current
by agonist was larger than a half of the first current. In
experiments with DRG neurons, after AITC was applied,
capsaicin (1 μM) was applied at the end of the recording
to identify whether IAITC was mediated by TRPA1 chan-
nels. Data were obtained in the event that the DRG
neurons were sensitive to both AITC and capsaicin
applications, since an IAITC in capsaicin-sensitive DRG
neurons is certainly a TRPA1-mediated event [29]. The
standard bath solution contained 140 mM NaCl, 5mM
KCl, 2 mM MgCl2, 2 mM CaCl2, 10 mM HEPES and
10 mM glucose, pH 7.4 (adjusted with NaOH). In some
experiment, the calcium-free bath solution contained
140 mM NaCl, 5 mM KCl, 2 mM MgCl2, 5 mM EGTA,
10 mM HEPES and 10 mM glucose, pH 7.4 (adjusted with
NaOH) was used. The pipette solution contained 140 mM
KCl, 5 mM MgATP, 5 mM EGTA and 10 mM HEPES,
pH 7.2 (adjusted with KOH). The concentration-response
curves for the effect of resveratrol on IAITC densities
(pA/pF) or PME on ICAP densities were fit by the Hill equa-
tion using KaleidaGraph 4.1 (Synergy Software, PA, USA).
All patch-clamp experiments were performed at room
temperature (~25C; RT). The solutions containing drugs
were applied to the chamber (1 ml) by a gravity system at a
flow rate of 4–5 ml/min.
Behavioral studies
Twenty-five or twenty-one male adult SD rats (200–250 g)
were used for the AITC- or capsaicin-induced nocifensive
behavioral analyses, respectively. Behavioral studies were
performed in accordance with the procedure of our previ-
ous reports [30,31]. To measure the effect of resveratrol
(or PME) on AITC-induced nocifensive behavior, after
adaptation, 50 μl resveratrol (300 μM, in saline) or PME
(300 μM, in saline) was injected intraplantarly into the rat
right hind paw. Five minutes after these injections,
rats received intradermal injection of 50 μl of AITC
(3% in liquid paraffin) to the same area of resveratrol
injected plantar surface. To measure the effect of PME
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after adaptation, 50 μl PME (300 μM, in saline) or
resveratrol (300 μM, in saline) was injected in the same
manner as above. Five minutes after these injections, rats
received intradermal injection of 50 μl of capsaicin (0.05%
in saline with 0.5% Tween20). The rats were placed in a
wire mesh cage immediately after the AITC or capsaicin
injection, and the number of hind paw flinches and du-
ration of licks per 5 min interval during the initial 30 min
post-injection period was measured. The total number of
flinches and total duration of licks during the entire initial
30 min for AITC or capsaicin was also calculated.
Statistical analysis
All results are expressed as mean ± SEM. An unpaired
t-test or one-way ANOVA was used to compare the
electrophysiological data between the groups. One-way
or two-way repeated ANOVA followed by Fisher’s PLSD
was applied to the behavioral data. A difference was
accepted as significant if the probability was less than
5% (p < 0.05).
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